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ANP = atrial natriuretic peptide; ARDS = acute respiratory distress syndrome; BNP = brain natriuretic peptide; CNP = C-type natriuretic peptide; IL =
interleukin; NP = natriuretic peptides; NPR = natriuretic peptide receptor; NT-proBNP = N-terminal proBNP; SIRS = systemic inflammatory
response syndrome.
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Introduction
Critical illness, such as sepsis, trauma and major surgery, is
accompanied by an activation of the immune system and
mediator cells; that is, macrophages elaborating soluble
inflammatory products such as cytokines and vasoactive
compounds. Acting in a complex network of mediator and
cell to cell interactions, inflammatory response in the most
severe clinical scenario evolves in multiple organ failure and
death [1]. Sepsis is defined by the presence of an infective
agent in combination with typical clinical and laboratory
findings of infection [2], although an infective organism is
found in fewer than 50% of cases [3]. It has been
increasingly recognized that sepsis represents only one
example of a systemic inflammatory response syndrome
(SIRS) that can be triggered not only by infection, but also
by noninfective disorders such as trauma or major surgery
[4,5].
Additive therapy strategies could not substantially lower the
mortality of sepsis and SIRS during the past 15 years [6];
mortality remained as high as 30–50%, accounting for at
least 225,000 deaths annually alone in the United States
[7,8]. In a recent large clinical trial, however, recombinant
human activated protein C, a compound with anticoagulant
and anti-inflammatory properties, has been found to reduce
mortality in patients with severe sepsis [9].
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Abstract
The present review will cover the mechanisms of release and the potential pathophysiological role of
different natriuretic peptides in critically ill patients. By focusing on the cardiovascular system,
possible implications of natriuretic peptides for diagnosis and treatment will be presented. In critical
illness such as sepsis, trauma or major surgery, systemic hypotension and an intrinsic myocardial
dysfunction occur. Impairment of the cardiovascular system contributes to poor prognosis in severe
human sepsis. Natriuretic peptides have emerged as valuable marker substances to detect left
ventricular dysfunction in congestive heart failure of different origins. Increased plasma levels of
circulating natriuretic peptides, atrial natriuretic peptide, N-terminal pro-atrial natriuretic peptide, brain
natriuretic peptide and its N-terminal moiety N-terminal pro-brain natriuretic peptide have also been
found in critically ill patients. All of these peptides have been reported to reflect left ventricular
dysfunction in these patients. The increased wall stress of the cardiac atria and ventricles is followed
by the release of these natriuretic peptides. Furthermore, the release of atrial natriuretic peptide and
brain natriuretic peptide might be triggered by members of the IL-6-related family and endotoxin in the
critically ill. Apart from the vasoactive actions of circulating natriuretic peptides and their broad effects
on the renal system, anti-ischemic properties and immunological functions have been reported for
atrial natriuretic peptide. The early onset and rapid reversibility of left ventricular impairment in
patients with good prognosis associated with a remarkably augmented plasma concentration of
circulating natriuretic peptides suggest a possible role of these hormones in the monitoring of therapy
success and the estimation of prognosis in the critically ill.
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The cardiovascular system in sepsis and
SIRS
The cardiovascular system is a major target in patients with
sepsis or SIRS, and depressed functions of this system
might directly influence outcome [10]. Thus, in the 40% of
patients with sepsis who develop cardiovascular impairment,
mortality rises to 70–90%, a percentage with only marginal
changes in recent years [11]. Peripheral vasodilatation
typically manifests as a systemic hypotension, hypo-
responsive to pressor agents, and an intrinsic myocardial
dysfunction commonly masked by a concomitant elevation in
cardiac index can be observed in these patients [10]. Most
severe alterations of the cardiovascular system were
frequently seen in patients with septic shock. The mechanisms
of myocardial depression in human septic shock involve a
complex network of vasoactive, Ca2+-regulative and
inflammatory mediators [12–15].
Myocardial depression and outcome in septic
shock
Survivors of septic shock were found to have a decreased
systolic function to an ejection fraction of about 33% and an
increase in left ventricular end-diastolic diameter. These
changes are of rapid onset and are reversible in survivors
within several days. In contrast, in nonsurvivors a progressive
myocardial depression early in the disease course has been
observed [16]. It has further been shown using trans-
oesophageal echocardiography that, apart from left
ventricular systolic dysfunction, left ventricular diastolic dys-
function may also occur in patients with septic shock [17].
The significance of diastolic dysfunction in sepsis and septic
shock has not yet been elucidated.
The natriuretic peptide system
The family of natriuretic peptides (NP) comprises at least
eight structurally related amino acid peptides stored as three
different prohormones: 126 amino acid atrial natriuretic
peptide (ANP) prohormone, 108 amino acid brain natriuretic
peptide (BNP) prohormone, and 126 amino acid C-type
natriuretic peptide (CNP) prohormone [18].
The ANP prohormone is synthesized mainly within the atrial
myocytes and in a variety of other tissues [19]. The
prohormone consisting of 126 amino acids contains several
peptides with blood pressure lowering properties, natriuretic
properties, diuretic properties and/or kaliuretic properties
[20]. These peptide hormones, numbered by their amino acid
sequences beginning at the N-terminal end of the ANP
prohormone, consist of the first 30 amino acids of the
prohormone (i.e. proANP 1–30; long-acting natriuretic
peptide), amino acids 31–67 (i.e. proANP 31–67; vessel
dilator), amino acids 79–98 (proANP 79–98; kaliuretic
peptide) and amino acids 99–126 (ANP) [20]. The ANP
prohormone processing is different within the kidney,
resulting in an additional four amino acids added to the N-
terminus of ANP (i.e. proANP 95–126; urodilatin) [21].
BNP, so named because of its initial isolation from the porcine
brain [22], has subsequently shown to be 10-fold more
abundant in the heart than in the brain [23]. BNP is processed
within the human heart to form 32 amino acid BNP, consisting
of amino acids 77–108 of its 108 amino acid prohormone,
and an N-terminal proBNP peptide (amino acids 1–76; NT-
proBNP), both of which circulate in humans [24].
CNP was originally found in the brain [25] and has been
subsequently suggested to be present also within the heart
[26]. In fact, CNP has been detected in human coronary
arteries [27] and in the peripheral circulation in endothelial
cells of human veins and arteries at various sites [28]. Two
CNP molecules, 22 and 53 amino acids in length, have been
identified within the circulation [25,26]. The 22 amino acid
form predominates in plasma and is more potent than the 53
amino acid form [26]. CNP lacks a significant natriuretic
function [29], and serves as a regulator of vascular tone
[30,31] and growth [32,33] in a paracrine or autocrine
fashion.
Actions of circulating NP
Apart from blood pressure lowering properties, natriuretic,
diuretic and/or kaliuretic properties of the NP originating from
the ANP prohormone [20] and from BNP, inhibition of the
renin–angiotensin system, sympathetic outflow, and vascular
smooth muscle and endothelial cell proliferation have been
attributed to NP [34]. Furthermore, a link of ANP to the
immune system has been suggested [35], and a receptor-
mediated modulation of macrophage function [36–38] and
priming of polymophonuclear neutrophils [39] have been
observed. Priming of neutrophils in endotoxemia is one of the
earliest alterations of these cells in the course of activation,
preceding expression of adhesion molecules and respiratory
burst triggered by inflammatory mediators (i.e. tumor necrosis
factor alpha and complement cascade) [40]. Whether NT-
proBNP has biological effects on its own is currently
unknown. The function of dendroaspis natriuretic peptide, the
most recent addition to the family of NP first isolated from the
venom of the green mamba, in humans still remains unclear
[41]. Atrial and ventricular volume expansion and pressure
overload are an adequate stimulus for secretion of circulating
natriuretic peptides deriving from ANP and BNP pro-
hormones, respectively [42,43].
Receptors of NP
Most biological effects of ANP and BNP are mediated by a
guanylate cyclase coupled cell surface receptor, the A-
receptor (NPR-A) [44]. Long-acting natriuretic peptide and
vessel dilator have distinct receptors separate from the ANP
receptors [45]. The natriuretic effects of the long-acting
natriuretic peptide and the vessel dilator have a different
mechanism of action from ANP, in that they inhibit renal
Na+-K+-ATPase secondary to their ability to enhance the
synthesis of prostaglandin E2 [46,47], which ANP does not
do [46,47].344
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CNP is a specific ligand for the B-receptor (NPR-B),
another guanylate cyclase coupled NP receptor [48]. The
third NP receptor, the so-called NP clearance receptor
(NPR-C), binds ANP, BNP and CNP. Apart from a major
role in the clearance of NP in the whole body [48], an
increasing number of reports describe that several effects
of ANP are mediated via the NPR-C receptor [49].
Stimulation of the NPR-C seems to be related to a G-
protein coupled inhibition of adenylate cyclase [50]. Apart
from binding to the NPRs, NP are cleared also through
proteolysis by peptidases, the most closely studied being
neutral endopeptidase 24.11. Renal excretion is currently
regarded as the main clearance mechanism for NT-proBNP,
but this topic awaits further study. All three subtypes of
natriuretic peptide receptors (i.e. NPR-A, NPR-B and NPR-
C) have been demonstrated to be expressed in diverse
tissues including the renal system and the animal and
human hearts [51].
NP in ischemia-reperfusion
In recent years it has been increasingly recognized that the
functions of the NP are not restricted to the regulation of
volume homeostasis. For instance, protective actions of ANP
against ischemia-reperfusion injury on whole organs have
been described first in the kidney [52] and in the liver [53].
This effect of ANP has been attributed to an antagonism of
catecholamine-mediated renal vasoconstriction [52], a
cGMP-mediated direct cytoprotective action on hepatocytes
[54] and a regulation of Kupffer cell function [55],
respectively. Protective actions against hypoxia and ischemia
have also been described for ANP and urodilatin at the heart
[56]. Since tissue hypoxia due to a deterioration of oxygen
utilization has been suspected in patients with sepsis [57],
antihypoxic and/or anti-ischemic effects of ANP at the cellular
level might be important also in primarily nonischemic
diseases such as sepsis. Apart from potential direct anti-
ischemic actions, the cardiac NP have received close
attention as cardiovascular markers. Following acute
myocardial infarction, plasma levels of ANP, N-terminal
proANP, vessel dilator, long-acting natriuretic peptide, BNP
and NT-proBNP have been found to be increased in patients
suffering from myocardial infarction [58–62]. BNP measured
between 1 and 4 days after an ST-segment elevation
myocardial infarction provides long-term prognostic
information [58,63] independent of left ventricular ejection
fraction [64]. Predictive information for use of risk
stratification has been provided for BNP in the whole
spectrum of acute coronary syndromes including patients
with nonpersistent ST-segment elevation [65]. N-terminal
proANP has also been reported to be an independent
predictor of long-term prognosis in humans when measured
3–16 days after infarction [66]. A prognostic value for long-
term prognosis after acute myocardial infarction [67,68] and
short-term prognosis after treatment with primary
percutaneous coronary intervention have also been described
for NT-proBNP [69].
NP and left ventricular dysfunction
Increased plasma levels of circulating NP have been
described in patients with congestive heart failure, and a
direct proportion assigned to the severity of congestive heart
failure as classified by the symptomatic New York Heart
Association has been reported for vessel dilator, for long-
acting natriuretic peptide, for BNP and for NT-proBNP
[70–73]. N-terminal proANP and BNP have been reported to
be more sensitive indicators of systolic left ventricular
dysfunction [74–76].
N-terminal proANP has been reported to identify patients with
asymptomatic left ventricular dysfunction with a sensitivity
and specificity of more than 90% [75]. For vessel dilator as
the only peptide (including ANP, BNP, NT-proBNP, etc.),
100% sensitivity and 100% specificity have been reported in
differentiating persons with mild congestive heart failure from
healthy individuals [71]. N-terminal proANP has also been
reported to be an independent predictor of the development
of congestive heart failure and of cardiovascular mortality
[66].
BNP and NT-proBNP have been shown to be useful markers
for prognosis in patients with asymptomatic left ventricular
dysfunction and different degrees of congestive heart failure
[76–78]. The major site of synthesis and release of BNP, the
cardiac ventricles, and BNP’s rapid upregulation by gene
expression followed by a remarkably augmented plasma
concentration exceeding that of ANP in severe cases [79],
make this peptide not only especially suitable to estimate the
severity of disease in patients with left ventricular dysfunction
[70], but may also help guide the treatment of systolic left
ventricular impairment in the future [80].
NP and pulmonary disease
In the urgent care setting it is often difficult to distinguish
between cardiac and pulmonary causes of dyspnea. Physical
signs, routine laboratory tests, electrocardiograms and chest
films are not diagnostically consistent in differentiating heart
failure from other disease, such as pulmonary disease [81].
Rapid testing of BNP and NT-proBNP has been reported to
differentiate pulmonary etiologies from cardiac etiologies of
dyspnea [82–84]. Some types of pulmonary disease, such as
cor pulmonale, pulmonary embolism and lung cancer,
however, are also associated with elevated natriuretic peptide
levels, but not generally to the same extent as those in
patients with acute left ventricular dysfunction. BNP levels in
the intermediate range from 100 to 500 pg/ml have been
reported to be attributable to causes other than congestive
heart failure [85].
Increased plasma levels of NP (i.e. ANP [86], N-terminal
proANP [87] and BNP [88]) have also been found in patients
with acute respiratory distress syndrome (ARDS). Acute cor
pulmonale as a consequence of increased pulmonary
vascular resistance occurs in up to 60% of patients with345
ARDS submitted to conventional mechanical ventilation [89].
An increase of pulmonary vascular resistance observed in
ARDS may lead to right ventricular overload and decreased
right ventricular output in presence of impaired right
ventricular contractility [90,91]. BNP levels secreted by the
right ventricular myocardium are said not to exceed
300–600 pg/ml [82]. However, there might be a
considerable overlap of patients with increased BNP due to
ARDS and patients with primary symptomatic congestive
heart failure, where BNP levels have to reach more than 500
pg/ml to ensure the diagnosis with a probability greater than
95% [92].
In support of this concept, elevated values reported for ANP
[86], N-terminal proANP [87], BNP [88] and NT-proBNP [93]
in patients with acute lung injury and/or sepsis are well in the
range found in patients with severe heart failure. These data
suggest at least for BNP a limited value of intermediate BNP
values for the discrimination of primary pulmonary disease
(i.e. ARDS) or cardiac disease. Sufficient data for other NP
are still lacking. In contrast, a BNP cutoff value of 100 pg/ml
measured at admission of patients presenting in the emer-
gency department has been reported to have a strong
negative predictive value for congestive heart failure in acute
dyspneic patients [73]. Nevertheless, a BNP cutoff value of
80 pg/ml was not able to exclude patients with ‘flash’
pulmonary edema [94]. Pulmonary edema and heart failure
are often found in patients (who are frequently old) with
diastolic dysfunction and a preserved systolic left ventricular
ejection fraction [95]. BNP might be useful in establishing the
diagnosis of (concomitant) diastolic dysfunction [96], which
is common in the elderly population with pulmonary disease.
However, although it could be confirmed by other
investigators that patients in the presence of diastolic
dysfunction had higher BNP levels compared with healthy
controls, in terms of absolute values symptomatic patients
with mild diastolic heart failure might have BNP levels in the
normal range [97].
Because of the overlap of BNP levels in the lower and
intermediate concentration, to date, the diagnostic value of
BNP in this concentration range seems to be poor. The major
role of BNP is thus still the separation of symptomatic
patients without congestive heart failure. Taking into
consideration the poor prognosis and higher readmission rate
in heart failure patients with increased levels of BNP (values
>500 pg/ml) [92], BNP and possibly further NP might have a
place in monitoring therapy success in the future. In this
regard, BNP might be of value also in patients with ARDS,
where a lack of BNP decrease has been related to prognosis
[88].
NP in the critically ill
Relation to endotoxin and proinflammatory cytokines
Hemodynamic changes typically seen in sepsis and septic
shock (i.e. reduced ejection fraction in presence of an
increased diastolic volume and pressure of both ventricles,
and an increase in pulmonary arterial pressure [10,98]) might
explain increased plasma levels of circulating NP derived
from both ventricles of the heart in those patients. ANP has
consistently been shown to increase in plasma during
hyperdynamic ovine endotoxemia associated with right
ventricular distension due to pulmonary hypertension, and in
acute respiratory failure associated with sepsis related to
pulmonary arterial and occlusion pressures [86,99–101].
Furthermore, a diminished pulmonary uptake in the case of a
reduced organ perfusion might contribute to the elevation in
plasma levels of ANP in sepsis. The lung is a major clearance
organ of ANP besides the liver, the kidney and the peripheral
and splanchnic circulation [102,103].
Plasma BNP has also been described as increased in animal
models dealing with endotoxemia [104]. However, it has
been questioned whether BNP expression and secretion in
endotoxemia is solely explained upon cardiac overloading due
to alterations of the cardiovascular system. A direct
upregulation of the BNP gene by lipopolysaccharide, not
mediated by other cytokines and independent from
mechanical loading in endotoxemia, has recently been
described in rats [104]. In fact, increased plasma levels of
endotoxin have also been found in other conditions
accompanied with increased BNP plasma levels (i.e.
congestive heart failure) [105], and endotoxin exerts
deleterious effects on cardiac performance itself [106,107].
Based on these findings, one might speculate that endotoxin
itself contributes to left ventricular dysfunction and modulates
BNP expression and secretion in addition to elevated
ventricular wall stress in endotoxemia in man.
Apart from endotoxin, proinflammatory cytokines stimulated in
different forms of heart failure and dramatically increased in
sepsis and septic shock might also contribute to ANP and
BNP secretion from the heart. In vitro studies have shown an
enhanced gene expression of BNP and prepro-ANP, the
precursor form of circulating ANPs, following stimulation of
cultured cardiomyocytes with IL-1β [108,109]. Increased
secretion of both ANP and BNP following stimulation with
members of the IL-6-related family (i.e. cardiotrophin-1) has
recently been reported in cultured cardiomyocytes [110]. In
heart failure, cardiotrophin-1 and IL-6 levels increase
[111,112], and cosecretion of IL-6 and ANP as well as of
cardiotrophin-1 and pro-BNP has been reported [111,113].
In human septic shock, ANP is related to IL-6 rather than to
the altered hemodynamics of these patients [114]. In septic
shock, IL-6 levels exceed those in ischemic or severe
congestive heart failure more than 100-fold [114,115], and
the relation between ANP and IL-6 seems to be rather
specific since no association between ANP and other
inflammatory mediators of septic shock (i.e. soluble tumor
necrosis factor receptors) could be observed [114]. These
findings argue for a possible role for members of the IL-6-
Available online http://ccforum.com/content/8/5/342346
related family in the modulation of both NP (ANP and BNP) in
patients suffering from ventricular impairment in septic shock.
Estimation of disease severity and prognosis
A negative relationship between heart function indices and
elevated plasma levels of ANP [116], N-terminal pro-ANP
[87] and, recently, for BNP [117] and NT-proBNP [93] has
been reported in human septic shock. These findings suggest
that these peptides might reflect myocardial dysfunction as
described in congestive heart failure in septic shock as well.
The relative value of ANP compared with BNP in recognition
of myocardial depression, severity of disease and outcome
prediction has been prospectively evaluated in human septic
shock [114]. In this study, cardiac impairment was reflected
by plasma BNP rather than by ANP [114]. Interestingly,
neither ANP nor BNP was related to the severity of disease
judged by the Acute Pathophysiology and Acute Chronic
Health Evaluation (APACHE) II score [114], and neither ANP
nor BNP was able to differentiate survivors from nonsurvivors
[114]. Although these results should be interpreted
cautiously because of the relatively small number of patients
included, the finding of a lack of value for prediction of the
severity of disease judged by the APACHE II score and
estimation of mortality is in good agreement with former
results in critically ill patients with a medium degree of
severity of illness [118]. Thus, in patients with trauma or
different kinds of surgery, neither ANP nor BNP were useful
for either estimation of disease severity or outcome prediction
[118].
In summary, BNP and to a minor degree ANP are associated
with the degree of cardiac impairment in septic shock. BNP
might therefore be the more suitable and valuable marker to
monitor therapy success. Actually, however, there is no
convincing evidence to establish a role of NP in estimation of
disease severity. Further studies are needed to clarify a feasible
role of NP in outcome prediction in human septic shock.
CNP in sepsis and inflammatory response
Although CNP is known to be a local regulator of vascular
tone and growth, CNP can be detected in human circulation
[119]. In contrast to other members of the natriuretic peptide
family, however, the plasma concentration of CNP is not
altered in heart disease such as congestive heart failure
[119]. So far, sepsis and further septic shock is the only
condition where sharply increased plasma levels of CNP have
been observed [119]. Tumor necrosis factor alpha, inducible
nitric oxide synthase and endotoxin, mediators all shown to
be increased in sepsis, are potent stimulators of CNP from
endothelial cells and might contribute to elevated plasma
levels of this peptide in sepsis [119]. Furthermore,
macrophages represent a source for and a target of CNP
[120]. In these mediator cells of inflammation, endotoxin has
been shown to induce CNP [121], and a B-receptor-
mediated inhibition of inducible nitric oxide synthase has
been described [122].
At the level of the vascular wall, CNP seems to act
predominantly at the vein [123]. It has been suspected that
increased concentrations of CNP might contribute to venous
pooling by vasodilative action on the vein in septic shock
[123].
Conclusion
Circulating NP such as ANP, peptides derived from the
N-terminal prohormone, BNP and its N-terminal moiety
NT-proBNP reflect a decreased left ventricular function in
patients with congestive heart failure, and play a role in risk
stratification in the whole spectrum of acute coronary
syndromes. Tissue hypoxia and impairment of left ventricular
function are often found in critically ill patients. NP such as
ANP, N-terminal proANP, BNP and NT-proBNP seem useful
to detect myocardial dysfunction early in the clinical course of
the critically ill. Myocardial dysfunction has been shown to be
associated with poor outcome in the critically ill, and
reversibility of cardiac impairment in patients with good
prognosis has been described. First results suggest a
possible role of circulating NP in monitoring of therapy
success in septic shock and perhaps in acute lung injury
associated with sepsis. Future studies are needed to confirm
a prognostic value of these natriuretic peptides in the
critically ill.
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